SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion announced the successful completion of the one-year extension…

Evaxion · PRESS-RELEASE filed Apr 7, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Apr 7, 2026 at 08:00 ET

Evaxion announced the successful completion of the one-year extension of its phase 2 trial for its personalized cancer vaccine EVX-01, with three-year clinical efficacy data expected in the second half of 2026. The trial has already shown a 75% Objective Response Rate and high durability, with 92% of patients still responding at two years and no relapses observed.

  • Phase 2 trial extension completed; final three-year data expected in H2 2026
  • Objective Response Rate of 75% (12 of 16 patients) with 4 complete responses
  • 92% of patients maintained response at two-year follow-up; no relapses observed
  • EVX-01 induced immune response in 100% of patients; 81% of targeted neoantigens generated potent T-cell responses

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access